Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ekaterine Asatiani"'
Publikováno v:
Contemporary Clinical Trials Communications, Vol 40, Iss , Pp 101329- (2024)
Background: Traditional dose selection for oncology registration trials typically employs a one- or two-step single maximum tolerated dose (MTD) approach. However, this approach may not be appropriate for molecularly targeted therapy, which tends to
Externí odkaz:
https://doaj.org/article/cf6b9d3798e44c5bb59d9d76b7beb11d
Autor:
James J. Harding, Christiane Jungels, Jean-Pascal Machiels, David C. Smith, Chris Walker, Tao Ji, Ping Jiang, Xin Li, Ekaterine Asatiani, Eric Van Cutsem, Ghassan K. Abou-Alfa
Publikováno v:
Targeted oncology, Vol. 18, no.2, p. 181-193 (2023)
INTRODUCTION: Fibroblast growth factor receptor (FGFR)-4/FGF19 pathway dysregulation is implicated in hepatobiliary and other solid tumors. INCB062079, an oral, selective, FGFR4 inhibitor, inhibits growth in FGF19/FGFR4-driven liver cancer models. ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f04505ca0b84ca2f39817875d1145645
https://lirias.kuleuven.be/handle/20.500.12942/720330
https://lirias.kuleuven.be/handle/20.500.12942/720330
Publikováno v:
International journal of cancerREFERENCES. 151(9)
Identifying the maximum tolerated dose (MTD) and recommending a Phase II dose for an investigational treatment is crucial in cancer drug development. A suboptimal dose often leads to a failed late-stage trial, while an overly toxic dose causes harm t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e637816c854fc48137a61c51c5b30f4
https://pubmed.ncbi.nlm.nih.gov/35802470
https://pubmed.ncbi.nlm.nih.gov/35802470
Autor:
Yan-ou Yang, Hong Yang, Betty Lamothe, Matthew Stubbs, Amanda McBride, Francis Seguy, Kevin Rockich, Jay Getsy, Phillip Wang, Xiang Liu, Jeff Jackson, Ekaterine Asatiani, Xuejun Chen
Publikováno v:
Cancer Research. 83:CT243-CT243
Disease-associated anemia is reported in over one-third of patients at MF diagnosis and can be exacerbated by currently available MF therapies. Further, anemia is associated with poor prognosis in MF. Activation of activin receptor-like kinase (ALK)-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93859577ab8b7b373ae124d270495707
https://doi.org/10.1158/1538-7445.am2023-ct243
https://doi.org/10.1158/1538-7445.am2023-ct243
Autor:
Amer M. Zeidan, Rachel J. Cook, Rodolfo Bordoni, James R. Berenson, William J. Edenfield, Sanjay Mohan, Gongfu Zhou, Ekaterine Asatiani, Nithya Srinivas, Michael R. Savona
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(7)
The Janus kinase (JAK)/signal transducers and activators of transcription pathway has been implicated in the pathogenesis and progression of various hematologic malignancies. JAK1-regulated cytokines stimulate proliferation and growth of malignant ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a596a4e7e09dc03674d62c394704e3
https://pubmed.ncbi.nlm.nih.gov/35260349
https://pubmed.ncbi.nlm.nih.gov/35260349
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Autor:
Tanios S, Bekaii-Saab, Juan W, Valle, Eric, Van Cutsem, Lorenza, Rimassa, Junji, Furuse, Tatsuya, Ioka, Davide, Melisi, Teresa, Macarulla, John, Bridgewater, Harpreet, Wasan, Mitesh J, Borad, Ghassan K, Abou-Alfa, Ping, Jiang, Christine F, Lihou, Huiling, Zhen, Ekaterine, Asatiani, Luis, Féliz, Arndt, Vogel
Publikováno v:
Future oncology (London, England). 16(30)
FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::98e7816bfea37b17ed2bf341f75c4654
https://pubmed.ncbi.nlm.nih.gov/32677452
https://pubmed.ncbi.nlm.nih.gov/32677452
Autor:
Luis Féliz, Swamy Yeleswaram, Ekaterine Asatiani, Tao Ji, Christine F. Lihou, Xuejun Chen, Robert R. Landman, Heather Overholt
Publikováno v:
Molecular Cancer Therapeutics. 18:C071-C071
Pemigatinib is a potent inhibitor of fibroblast growth factor receptors (FGFR) 1, 2, and 3 with selectivity against other kinases and is currently being studied in solid tumors expressing FGFR translocations and/or mutations. A first-in-man phase 1 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0dd0aaa01fbc17faa7ba2548c976b98
https://doi.org/10.1158/1535-7163.targ-19-c071
https://doi.org/10.1158/1535-7163.targ-19-c071
Autor:
Helen X. Chen, Monica M. Mita, Lacey McQuinn, Lawrence A. Doyle, Siqing Fu, Xiaochun Liu, Kenneth R. Hess, Aung Naing, David S. Hong, Razelle Kurzrock, Sarina Anne Piha-Paul, Ekaterine Asatiani, Patricia LoRusso
Publikováno v:
The Oncologist. 19:426-428
Mucositis may limit the therapeutic window for mammalian target of rapamycin inhibitor-based combination therapy, necessitating treatment interruptions and/or dose reductions. Optimizing treatment or prophylactic interventions for mucositis will enab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe783884beeb504ab2db8e797a55e824
https://doi.org/10.1634/theoncologist.2013-0231
https://doi.org/10.1634/theoncologist.2013-0231
Autor:
Hui-Ling Zhen, Ekaterine Asatiani, Jean-Jacques Kiladjian, Srdan Verstovsek, Juan Carlos Hernandez Boluda, Andreas Hochhaus, Andreas Reiter, Alessandro Rambaldi, Adam J. Mead, Christine F. Lihou, Jason Gotlib, Alessandro M. Vannucchi
Publikováno v:
Blood. 132:690-690
Introduction: Myeloid/lymphoid neoplasms (MLNs) with rearrangement of FGFR1 on chromosome band 8p11 are rare but aggressive neoplasms characterized by heterogeneous presentation with myeloid and/or lymphoid proliferation, extramedullary involvement,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::930b886e561a101f329bf2fba6cf277f
https://doi.org/10.1182/blood-2018-99-110388
https://doi.org/10.1182/blood-2018-99-110388